Migraine and Hormonal contraception

Deep Dive

From a western clinical perspective, the relationship between migraine and hormonal contraception is defined by two intersecting considerations:... From a western clinical perspective, the relationship between migraine and hormonal contraception is defined by two intersecting considerations: hormonal dynamics that modulate headache patterns, and vascular risks that shape safety. Estrogen fluctuations—particularly the decline in late luteal phase—are a well‑described migraine trigger. Cyclic combined hormonal contraceptives (CHCs) reproduce this physiology with a hormone‑free interval, during which estrogen withdrawal can precipitate menstrual migraines. In contrast, extended or continuous CHC regimens reduce or eliminate the hormone‑free interval, thereby minimizing estrogen withdrawal and, in eligible users, may decrease menstrual‑related attacks. Ultra‑low‑dose ethinyl estradiol formulations may also be better tolerated by some. However, safety drives method selection. Migraine with aura independently carries a small but measurable ischemic stroke risk, which is magnified by exogenous estrogen. Large observational datasets and consensus statements conclude that CHCs meaningfully increase ischemic stroke risk in people with migraine with aura; national guidelines therefore classify CHCs as contraindicated in this group. The risk rises further with additional factors such as age ≥35, cigarette smoking, hypertension, hyperlipidemia, diabetes, or thrombophilia. In contrast, progestin‑only contraception—including progestin‑only pills, the etonogestrel implant, levonorgestrel intrauterine device (LNG‑IUD), and depot medroxyprogesterone—does not appear to increase stroke risk and is considered acceptable for people with migraine, including those with aura. LARC options (implant, LNG‑IUD) provide highly effective contraception with stable or local progestin exposure and are typically migraine‑neutral; some users report fewer perimenstrual headaches due to reduced bleeding and prostaglandin release. The copper IUD avoids hormones entirely and leaves migraine patterns to reflect baseline biology. Clinically, shared decision‑making balances contraceptive efficacy, bleeding profiles, migraine phenotypes (with or without aura, menstrual pattern), and vascular risk. Practical options include progestin‑only and non‑hormonal methods for those with aura or elevated vascular risk; and, for those without aura and otherwise low risk, consideration of continuous/extended CHC to reduce estrogen withdrawal. Red flags that warrant prompt evaluation include new or worsening focal neurological symptoms, first or markedly different headache, aura lasting longer than usual, or onset of aura after starting estrogen‑containing contraception. Co‑management with neurology or gynecology is helpful when diagnosis is uncertain, attacks escalate after a method change, or preventive migraine therapy is being initiated alongside contraceptive selection.